1-氯-2,3-吲哚二酮 | 2959-03-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1-氯-2,3-吲哚二酮
• 英文名称: 1-chloroisatin
• 英文别名: 1-Chloro-1H-indole-2,3-dione；1-Chloro-2,3-indoledione；1-chloroindole-2,3-dione
• CAS: 2959-03-7
• 化学式: C₈H₄ClNO₂
• mdl: MFCD00043698
• 分子量: 181.578
• InChiKey: ZGPFGHSOYPBCGI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

文献信息

• [EN] QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF<br/>[FR] COMPOSÉS DE QUINOLÉINE UTILISÉS EN TANT QUE MODULATEURS DE L'ACTIVITÉ DE RAGE ET LEURS UTILISATIONS
  申请人：UNIV NEW YORK

  公开号：WO2017184547A1

  公开（公告）日：2017-10-26

  Quinoline compounds are disclosed that have a formula represented by the following: and wherein Cy, R1, R4a, R4b, and n are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diabetes complications, inflammation, and neurodegeneration, obesity, cancer, ischemia/reperfusion injury, cardiovascular disease and other diseases related to RAGE activity.

  披露了具有以下公式表示的喹啉化合物：其中Cy、R1、R4a、R4b和n如本文所述。这些化合物可以制备为药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，例如糖尿病并发症、炎症、神经退行性疾病、肥胖、癌症、缺血/再灌注损伤、心血管疾病和其他与RAGE活性相关的疾病。
• [EN] PYRROLOTHIAZOLE CONTAINING CURCUMIN COMPOUNDS<br/>[FR] COMPOSÉS DE CURCUMINE CONTENANT UN PYRROLOTHIAZOLE
  申请人：UNIV SAINS MALAYSIA

  公开号：WO2012099453A1

  公开（公告）日：2012-07-26

  Accordingly, the invention discloses compounds of pyrrolothiazole moiety containing with mono bis substituted curcumin molecules which improves solubility of curcumin. The invention also discloses the method in synthesizing these compounds wherein the steps includes mixing curcumin, isatin derivatives or ninhydrin and thioproline (thiazolidine-4-carboxylic acid) in 20 mL methanol. The mixture was then refiuxed with a solvent on a water bath and excess solvent was removed under vacuum. The residue subjected to flash column chromatography using petroleum ether: ethyl acetate mixture (4:1) as eluent to afford the product. The ratio for curcumin: isatin derivative/ninhydrin:thioproline (thiazolidine-4-carboxylic acid) is 1:1:2 and 1:2:4.

  因此，该发明揭示了含有单双取代姜黄素分子的吡咯噻唑基团化合物，该化合物可提高姜黄素的溶解性。该发明还揭示了合成这些化合物的方法，其中步骤包括将姜黄素、吲哚啉衍生物或吲哚酮和硫丙氨酸脯氨酸（噻唑烷-4-羧酸）混合在20毫升甲醇中。然后，在水浴中与溶剂回流混合物，并在真空下去除过量溶剂。残留物经过快速柱层析，使用石油醚：乙酸乙酯混合物（4:1）作为洗脱剂得到产物。姜黄素：吲哚啉衍生物/吲哚酮：硫丙氨酸脯氨酸（噻唑烷-4-羧酸）的比例为1:1:2和1:2:4。
• [EN] CURCUMIN COMPOUNDS WITH SUPERIOR STRUCTURAL STABILITY AND PROCESSES FOR THEIR PREPARATION<br/>[FR] COMPOSÉS DE CURCUMINE AYANT UNE STABILITÉ STRUCTURALE SUPÉRIEURE ET PROCÉDÉS POUR LEUR PRÉPARATION
  申请人：UNIV SAINS MALAYSIA

  公开号：WO2012099452A1

  公开（公告）日：2012-07-26

  Accordingly, the invention discloses compounds with enhanced bioavailability for the prevention and treatment of anti-human immunodeficiency virus (HIV), anti-tuberculosis (TB), anti-Alzheimer or anti-cancer. The invention also discloses the method in synthesizing these compounds wherein the steps includes mixing curcumin, isatin derivatives or ninhydrin and proline in 20 mL methanol. The mixture was then refluxed with a solvent on a water bath and excess solvent was removed under vacuum. The residue subjected to flash column chromatography using petroleum ether: ethyl acetate mixture (4:1) as eluent to afford the product. The ratio for curcumin: isatin derivative/ninhydrin:proline is 1 :1 :2 and 1 :2:4.

  因此，该发明揭示了增强生物利用度的化合物，用于预防和治疗抗人类免疫缺陷病毒（HIV）、抗结核病（TB）、抗阿尔茨海默病或抗癌症。该发明还揭示了合成这些化合物的方法，其中步骤包括将姜黄素、异色草酮衍生物或萘酚和脯氨酸混合在20毫升甲醇中。然后将混合物在水浴上用溶剂回流，并在真空下去除过量溶剂。残留物经过闪蒸柱层析，使用石油醚：乙酸乙酯混合物（4:1）作为洗脱剂，得到产物。姜黄素：异色草酮衍生物/萘酚：脯氨酸的比例为1:1:2和1:2:4。
• [EN] CURCUMIN COMPOUNDS CONTAINING INDOLIZINE AND THEIR PREPARATIONS THEREOF<br/>[FR] COMPOSÉS DE CURCUMINE CONTENANT DE L'INDOLIZINE ET LEURS PRÉPARATIONS
  申请人：UNIV SAINS MALAYSIA

  公开号：WO2012099451A1

  公开（公告）日：2012-07-26

  Accordingly, the invention discloses compounds with enhanced bioavailability for the prevention and treatment of anti-human immunodeficiency virus (HIV), anti- tuberculosis (TB), anti-Alzheimer or anti-cancer. The invention also discloses the method in synthesizing these compounds wherein the steps includes mixing curcumin, isatin derivatives or ninhydrin and pipecolinic acid in 20 m L methanol. The mixture was then refluxed with a solvent on a water bath and excess solvent was removed under vacuum. The residue subjected to flash column chromatography using petroleum ether: ethyl acetate mixture (4:1) as eluent to afford the product. The ratio for curcumin: isatin derivative/ninhydrin: pipecolinic acid is 1:1:2 and 1:2:4.

  因此，本发明揭示了一种增强生物利用度的化合物，用于预防和治疗抗人类免疫缺陷病毒（HIV）、抗结核病（TB）、抗阿尔茨海默病或抗癌症。本发明还揭示了合成这些化合物的方法，其中步骤包括将姜黄素、异色烟酰肼衍生物或吡啶甲酸混合在20毫升甲醇中。然后将混合物在水浴上用溶剂回流，并在真空下去除多余的溶剂。残留物经过闪蒸柱层析，使用石油醚：乙酸乙酯混合物（4:1）作为洗脱剂，得到产物。姜黄素：异色烟酰肼衍生物/吡啶甲酸的比例为1:1:2和1:2:4。
• BCL6 INHIBITORS AS ANTICANCER AGENTS
  申请人：Cornell University

  公开号：US20160166549A1

  公开（公告）日：2016-06-16

  The invention provides compositions and methods for blocking the BCL6 BTB domain with small molecule, non-peptide compounds as disclosed and claimed herein. BCL6 is a transcriptional repressor of the BTB-POZ (brie a brae, tramtrack, broad complex/pox virus zincfinger) family of proteins. It is required for normal development of germinal center (GC) B-cells and is also the most commonly involvedoncogene in diffuse large B-celllymphomas (DLBCLs), and constitutive expression of BCL6 in GC B-cells causes DLBCL in mice.

  本发明提供了一种使用小分子非肽化合物阻断BCL6 BTB结构域的组合物和方法，如本文所述和索要的。BCL6是BTB-POZ（brie a brae，tramtrack，broad complex/pox virus zincfinger）蛋白家族的转录抑制因子。它是生殖中心（GC）B细胞正常发育所必需的，并且也是弥漫性大B细胞淋巴瘤（DLBCLs）中最常涉及的癌基因，GC B细胞中的BCL6的构成表达会导致小鼠DLBCL。

表征谱图